Pacira BioSciences, Inc.

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-24 pm EST			5-day change	1st Jan Change
24.52 ^USD	+5.10%		+9.66%	+30.15%

Jan. 21	Pacira BioSciences, Inc. Announces Appointment of Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer	CI
Jan. 15	Pacira BioSciences, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 10:30 AM

Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024

November 06, 2024 at 04:02 pm EST

Pacira BioSciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported revenue was USD 168.57 million compared to USD 163.93 million a year ago. Net loss was USD 143.47 million compared to net income of USD 10.86 million a year ago. Basic loss per share from continuing operations was USD 3.11 compared to basic earnings per share from continuing operations of USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 3.11 compared to diluted earnings per share from continuing operations of USD 0.23 a year ago.
For the nine months, revenue was USD 513.71 million compared to USD 493.73 million a year ago. Net loss was USD 115.6 million compared to net income of USD 17.09 million a year ago. Basic loss per share from continuing operations was USD 2.5 compared to basic earnings per share from continuing operations of USD 0.37 a year ago. Diluted loss per share from continuing operations was USD 2.5 compared to diluted earnings per share from continuing operations of USD 0.37 a year ago.

Latest news about Pacira BioSciences, Inc.

Pacira BioSciences, Inc. Announces Appointment of Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer	Jan. 21	CI
Pacira BioSciences, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 10:30 AM	Jan. 15
Sector Update: Health Care Stocks Weaker Late Afternoon	Jan. 10	MT
Pacira Biosciences Reports Preliminary 2024 Revenue Rose, Outlines Five-Year Plan	Jan. 10	MT
Pacira BioSciences, Inc. Reports Preliminary Unaudited Revenue Results for the Year Ended December 31, 2024	Jan. 10	CI
Pacira Biosciences Gets FDA Clearance for Chronic Low Back Pain Treatment	Jan. 07	MT
Pacira BioSciences, Inc. Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block	Jan. 07	CI
RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating	Jan. 07	MT
Pacira Biosciences Shareholder DOMA Perpetual Capital Management to Nominate 4 Director Candidates	Dec. 11	MT
DOMA Perpetual Capital Management Intends to Nominate Candidates at 2025 Annual Meeting of Pacira BioSciences	Dec. 11	CI
Pacira BioSciences Receives US Patent for Exparel Composition	Dec. 03	MT
Pacira BioSciences, Inc. Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee	Nov. 14	CI
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating	Nov. 07	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 EPS $0.83	Nov. 06	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 EPS $0.83	Nov. 06	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q3 Revenue $168.6M	Nov. 06	MT
Pacira BioSciences, Inc., Q3 2024 Earnings Call, Nov 06, 2024	Nov. 06
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 7, 2024.	Nov. 06	CI
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI
Pacira BioSciences, Inc. Reports Goodwill Impairment for the Third Quarter Ended September 30, 2024	Nov. 06	CI
Pacira BioSciences, Inc. Reiterates Earnings Guidance for the Full-Year 2024	Nov. 06	CI
Pacira Biosciences Names Shawn Cross CFO	24-10-21	MT
Pacira BioSciences, Inc. Announces Chief Financial Officer Changes	24-10-21	CI
RBC Raises Price Target on Pacira BioSciences to $15 From $14, Keeps Sector Perform Rating	24-10-04	MT
Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025	24-10-03	CI

Chart Pacira BioSciences, Inc.

Duration

Period

PCRX: Dynamic Chart

Company Profile

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Employees

712

Sector

Pharmaceuticals

Calendar

2025-02-26 - Q4 2024 Earnings Release (Projected)

More about the company